1
|
Grigioni S, Lvovschi VE, Tamion F, Joly LM, Coëffier M, Van Elslande H, Galmiche M, Gâté M, Traore-Ouattara U, Marais B, Michel J, Dechelotte P, Savoye-Collet C, Achamrah N. Low thoracic skeletal muscle index is associated with negative outcomes in 244 patients with respiratory COVID-19. Clin Nutr 2023; 42:102-107. [PMID: 36521254 PMCID: PMC9674398 DOI: 10.1016/j.clnu.2022.11.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 10/27/2022] [Accepted: 11/09/2022] [Indexed: 11/20/2022]
Abstract
BACKGROUND Sarcopenia is associated with negative outcomes in intensive care unit (ICU) patients and during chronic diseases. We aimed to evaluate if low skeletal muscle index (SMI) measured by computed tomography (CT) at the thoracic level is associated with poor outcomes in hospitalized patients with respiratory COVID-19. METHODS Patients admitted to the hospital between March 1st and June 9, 2020 with a confirmed diagnosis of respiratory COVID-19 in the Emergency Department were included in this retrospective cohort study. SMI was assessed from a transverse CT image at the T12 level. We analysed the association between thoracic SMI and mortality, ICU admissions, infections, length of stay and gravity scores. RESULTS We included 244 patients, whose median age was 62 (20-95) years, mean body mass index was 28,6 kg/m2, and 34% were obese patients. 102 patients (41,8%) had low thoracic SMI. On multivariable analysis, low thoracic SMI was associated with more infections (OR = 1,88 [1,06-2,98]) and increased length of stay (OR = 1,87 [1,14-3,49]) but not with mortality (OR = 1.37 [0.54-3.52]), whereas it was inversely associated with ICU admission (OR = 5,56 [1,96-16,67]. CONCLUSION Low SMI measured by CT at the thoracic level T12 is associated with negative outcomes in patients with respiratory COVID-19.
Collapse
Affiliation(s)
- S Grigioni
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | - V-E Lvovschi
- Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Emergency Department, CHU Rouen, Rouen, France
| | - F Tamion
- Medical Intensive Care Unit, CHU Rouen, France; Normandie Univ, UNIROUEN, INSERM U1096, F-76000 Rouen, France
| | - L-M Joly
- Emergency Department, CHU Rouen, Rouen, France
| | - M Coëffier
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | - H Van Elslande
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | | | - M Gâté
- Nutrition Department, CHU Rouen, Rouen, France
| | | | - B Marais
- Medical Intensive Care Unit, CHU Rouen, France
| | - J Michel
- Emergency Department, CHU Rouen, Rouen, France
| | - P Dechelotte
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | | | - N Achamrah
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France.
| |
Collapse
|
2
|
Galmiche M, Achamrah N, Déchelotte P, Ribet D, Breton J. Role of microbiota-gut-brain axis dysfunctions induced by infections in the onset of anorexia nervosa. Nutr Rev 2021; 80:381-391. [PMID: 34010427 DOI: 10.1093/nutrit/nuab030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by low food intake, severe body weight loss, intense fear of gaining weight, and dysmorphophobia. This chronic disease is associated with both psychiatric and somatic comorbidities. Over the years, clinical studies have accumulated evidence that viral or bacterial infections may promote the onset of eating disorders such as AN. This review aims to describe how infections and the subsequent immune responses affect food intake regulation in the short term and also how these processes may lead to long-term intestinal disorders, including gut barrier disruption and gut microbiota dysbiosis, even after the clearance of the pathogens. We discuss in particular how infection-mediated intestinal dysbiosis may promote the onset of several AN symptoms and comorbidities, including appetite dysregulation, functional gastrointestinal disorders, and mood disorders.
Collapse
Affiliation(s)
- Marie Galmiche
- M. Galmiche, N. Achamrah, P. Déchelotte, and J. Breton are with Nutrition Department, CHU Rouen, F-76000 Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, INSERM UMR 1073, Nutrition, Gut and Brain Laboratory, Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France
| | - Najate Achamrah
- M. Galmiche, N. Achamrah, P. Déchelotte, and J. Breton are with Nutrition Department, CHU Rouen, F-76000 Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, INSERM UMR 1073, Nutrition, Gut and Brain Laboratory, Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France
| | - Pierre Déchelotte
- M. Galmiche, N. Achamrah, P. Déchelotte, and J. Breton are with Nutrition Department, CHU Rouen, F-76000 Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, INSERM UMR 1073, Nutrition, Gut and Brain Laboratory, Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France
| | - David Ribet
- M. Galmiche, N. Achamrah, P. Déchelotte, and J. Breton are with Nutrition Department, CHU Rouen, F-76000 Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, INSERM UMR 1073, Nutrition, Gut and Brain Laboratory, Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France
| | - Jonathan Breton
- M. Galmiche, N. Achamrah, P. Déchelotte, and J. Breton are with Nutrition Department, CHU Rouen, F-76000 Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, INSERM UMR 1073, Nutrition, Gut and Brain Laboratory, Rouen, France. N. Achamrah, P. Déchelotte, D. Ribet, and J. Breton are with the UNIROUEN, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France
| |
Collapse
|
3
|
Dominique M, Legrand R, Galmiche M, Saïda A, Deroissart C, Guérin C, do Rego JL, Léon F, Nobis S, Lambert G, Lucas N, Déchelotte P. Modifications des entérobactéries et de la protéine ClpB dans un modèle de restriction alimentaire chez la souris : implications possibles pour l’étiologie et la perpétuation de l’anorexie mentale. NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Galmiche M, Lucas N, Déchelotte P, Deroissart C, Le Solliec MA, Rondeaux J, Azhar S, Grigioni S, Colange G, Delay J, Achamrah N, Folope V, Belmonte L, Lamarre A, Rimbert A, Saillard T, Petit A, Quillard M, Coeffier M, Gillibert A, Lambert G, Legrand R, Tavolacci MP. Plasma Peptide Concentrations and Peptide-Reactive Immunoglobulins in Patients with Eating Disorders at Inclusion in the French EDILS Cohort (Eating Disorders Inventory and Longitudinal Survey). Nutrients 2020; 12:nu12020522. [PMID: 32085628 PMCID: PMC7071399 DOI: 10.3390/nu12020522] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 02/11/2020] [Accepted: 02/14/2020] [Indexed: 12/12/2022] Open
Abstract
Eating disorders (EDs) are increasingly frequent. Their pathophysiology involves disturbance of peptide signaling and the microbiota–gut–brain axis. This study analyzed peptides and corresponding immunoglobulin (Ig) concentrations in groups of ED. In 120 patients with restrictive (R), bulimic (B), and compulsive (C) ED, the plasma concentrations of leptin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and insulin were analyzed by Milliplex and those of acyl ghrelin (AG), des-acyl ghrelin (DAG), and α-melanocyte-stimulating hormone (α-MSH) by ELISA kits. Immunoglobulin G (in response to an antigen) concentrations were analyzed by ELISA, and their affinity for the respective peptide was measured by surface plasmon resonance. The concentrations of leptin, insulin, GLP-1, and PYY were higher in C patients than in R patients. On the contrary, α-MSH, DAG, and AG concentrations were higher in R than in C patients. After adjustment for body mass index (BMI), differences among peptide concentrations were no longer different. No difference in the concentrations of the IgG was found, but the IgG concentrations were correlated with each other. Although differences of peptide concentrations exist among ED subtypes, they may be due to differences in BMI. Changes in the concentration and/or affinity of several anti-peptide IgG may contribute to the physiopathology of ED or may be related to fat mass.
Collapse
Affiliation(s)
- Marie Galmiche
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
| | - Nicolas Lucas
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Pierre Déchelotte
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
- Correspondence: ; Tel.: +06-08-49-66-26
| | - Camille Deroissart
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Marie-Anne Le Solliec
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Julie Rondeaux
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Saida Azhar
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Sébastien Grigioni
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Guillaume Colange
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Julie Delay
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Najate Achamrah
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Vanessa Folope
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Liliana Belmonte
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Adèle Lamarre
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Agnès Rimbert
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Tiphaine Saillard
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - André Petit
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - Muriel Quillard
- CIC-CRB 1404 INSERM, University Hospital of Rouen, 76000 Rouen, France;
| | - Moise Coeffier
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- Nutrition unit, University Hospital of Rouen, 76000 Rouen, France; (G.C.); (J.D.); (A.L.); (T.S.)
| | - André Gillibert
- Department of Biostatistics, Rouen University Hospital, F 76000 Rouen, France;
| | - Grégory Lambert
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Romain Legrand
- TargEDys SA, 91160 Longjumeau, France; (N.L.); (C.D.); (M.-A.L.S.); (J.R.); (S.A.); (G.L.); (R.L.)
| | - Marie-Pierre Tavolacci
- Inserm UMR1073, 76000 Rouen, France; (M.G.); (S.G.); (N.A.); (V.F.); (L.B.); (A.R.); (A.P.); (M.C.); (M.-P.T.)
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France
- CIC-CRB 1404 INSERM, University Hospital of Rouen, 76000 Rouen, France;
| |
Collapse
|
5
|
Renaud S, Stravodimou A, Fiche M, Xenarios I, Valentina S, Dormoy V, Galmiche M, Brisken C, Delaloye JF, Treboux A, Meuwly JY, Mermod N, Zaman K. Abstract P6-10-22: miR363-3p mediates maintenance of breast cancer stem cells (BCSCs) and predicts resistance to neoadjuvant chemotherapy and disease recurrence. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-10-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Increasing data support the role of BCSCs in recurrence and resistance to chemotherapy. However, detecting these cells specifically and targeting them therapeutically remain challenging. We set to identify miRNAs involved in chemoresistance of BCSCs in vitro and the results were assessed in the sera of healthy donors and breast cancer patients treated with neoadjuvant chemotherapy (NAC). Methods In vitro experiments were conducted in the MCF7 cell line grown as mammospheres (MS) in order to enrich a BCSC phenotype. After treatment with 5FU or Paclitaxel (Pac), microRNA profile of chemoresistant cells was analyzed by microarray. The results were compared to miRNAs found in immortalized non-tumorigenic MCF10A cells in order to exclude miRNAs related to normal stem cells. A signature of 6 miRNAs was identified. miR-363-3p, appearing the most relevant, was chosen for further assessment. By RT-qPCR, miR363-3p levels were 20- and 100-fold higher in ALDH+ sorted cells compared to ALDH- MCF7 and MDA-MB-231 cells, respectively. Moreover, overexpression of miR363-3p in MCF7 cells correlated with an increased number of ALDH+ cells and 1.5 more MS formed. In contrast, downregulation of miR363-3p levels induced a decrease in MS size and 2-fold reduction in number. Consistently, miR-363-3p downregulation decreased tumor growth and metastasis of MCF7 cells in an intraductal human-in-mice transplantation model. miRNA was quantified by RT-qPCR in tissue and sera collected prospectively from 40 breast cancer patients before and after NAC (anthracycline-taxane) and also from 25 healthy donors. Results Fifty percent of the patients had luminal A and B tumors (n=20), 32,5% (n=13) had triple negative breast cancer (TNBC), and 17.5% (n=7) had HER2 positive BC. Excluding one patient, who refused the surgical resection, 40% achieved pathological complete response (pCR). Six patients presented disease recurrence. In patients’ tumor before and after NAC, a higher level of miR363-3p was observed compared with benign tissue. In sera of the BC patients, miR363-3p levels were significantly higher than that of healthy donors. After NAC, the levels of miR363-3p remained high among patients who relapsed, whereas they were equivalent to the healthy donors in patients who remained in remission. No correlation between Ki-67, grade 1 or 2 and miR363-3p levels was observed. However, in grade 3 BC, low level of miR363-3p before and after NAC was correlated with pCR and remission. The level of miR363-3p correlated with remission and pCR in patients with TNBC and HER2 BC. Conclusions Assessment in the sera of patients and healthy donors confirms our previous data supporting the role of miR363-3p as predictive factor of resistance to neoadjuvant chemotherapy and disease recurrence. Further investigations are warranted to confirm the role of miR363-3p as a biomarker and potential therapeutic target.
Citation Format: Stephanie Renaud, Athina Stravodimou, Maryse Fiche, Ioannis Xenarios, Scabia Valentina, Valerian Dormoy, Marie Galmiche, Cathrin Brisken, Jean-Francois Delaloye, Assia Treboux, Jean-Yves Meuwly, Nicolas Mermod, Khalil Zaman. miR363-3p mediates maintenance of breast cancer stem cells (BCSCs) and predicts resistance to neoadjuvant chemotherapy and disease recurrence [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-10-22.
Collapse
Affiliation(s)
| | | | - Maryse Fiche
- 1University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | | | - Scabia Valentina
- 3Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale (EPFL), Lausanne, Switzerland
| | - Valerian Dormoy
- 4INSERM UMR-S 1250,University of Reims Champagne-Ardenne (URCA), Reims, France
| | - Marie Galmiche
- 1University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | - Cathrin Brisken
- 3Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale (EPFL), Lausanne, Switzerland
| | | | - Assia Treboux
- 1University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | | | - Nicolas Mermod
- 3Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale (EPFL), Lausanne, Switzerland
| | - Khalil Zaman
- 1University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| |
Collapse
|
6
|
Dominique M, Legrand R, Galmiche M, Azhar S, Deroissart C, Guérin C, do Rego JL, Leon F, Nobis S, Lambert G, Lucas N, Déchelotte P. Changes in Microbiota and Bacterial Protein Caseinolytic Peptidase B During Food Restriction in Mice: Relevance for the Onset and Perpetuation of Anorexia Nervosa. Nutrients 2019; 11:E2514. [PMID: 31635300 PMCID: PMC6835841 DOI: 10.3390/nu11102514] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 10/14/2019] [Accepted: 10/15/2019] [Indexed: 02/06/2023] Open
Abstract
Microbiota contributes to the regulation of eating behavior and might be implicated in the pathophysiology of anorexia nervosa. ClpB (Caseinolytic peptidase B) protein produced mainly by the Enterobacteriaceae family has been identified as a conformational mimetic of α-MSH, which could result in similar anorexigenic effects. The aim of this study was to highlight the role of the microbiome and the ClpB protein in deregulation and self-maintenance of anorexia pathology. Male C57Bl/6 mice were undergone to the ABA (Activity-Based Anorexia) protocol: after 5 days of acclimatization, both ABA and LFA (Limited Food Access) mice had progressively limited access to food until D17. At the end of protocol, the plasma ClpB concentration and Enterobacteriaceae DNA in colonic content were measured. As expected, dietary restriction induced lost weight in LFA and ABA mice. At D10, colonic permeability and plasma concentration of the ClpB protein were significantly increased in LFA and ABA mice vs. controls. At D17, plasma concentration of ClpB was increased in LFA and ABA mice and, it was correlated with proportion of Enterobacteriaceae in the faeces. These abnormally high ClpB concentrations and all associated factors, and therefore might contribute to the initiation and/or perpetuation of anorexia nervosa by interfering with satiety signaling.
Collapse
Affiliation(s)
- Manon Dominique
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Romain Legrand
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Marie Galmiche
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Saïda Azhar
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | | | - Charlène Guérin
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Fatima Leon
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Séverine Nobis
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Grégory Lambert
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Nicolas Lucas
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Pierre Déchelotte
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Rouen University Hospital, CHU Charles Nicolle, 76183 Rouen, France.
| |
Collapse
|
7
|
Galmiche M, Déchelotte P, Lambert G, Tavolacci MP. Prevalence of eating disorders over the 2000-2018 period: a systematic literature review. Am J Clin Nutr 2019; 109:1402-1413. [PMID: 31051507 DOI: 10.1093/ajcn/nqy342] [Citation(s) in RCA: 554] [Impact Index Per Article: 110.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 10/30/2018] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Eating disorders (EDs) lead to multiple psychiatric and somatic complications and thus constitute a major public health concern. OBJECTIVES The aim of this study was to give an exhaustive view of the studies reporting the prevalence of the different EDs or total EDs and to study their evolution. METHODS A literature search following PRISMA Guidelines and limited to studies in English or French published between 2000 and 2018 was performed and relevant studies were included in this systematic review on the prevalence of EDs. The literature search revealed 94 studies with accurate ED diagnosis and 27 with broad ED diagnosis. RESULTS In 94 studies with accurate ED diagnosis, the weighted means (ranges) of lifetime ED were 8.4% (3.3-18.6%) for women and 2.2% (0.8-6.5%) for men. The weighted means (ranges) of 12-month ED prevalence were 2.2% (0.8-13.1%) for women and 0.7% (0.3-0.9%) for men. The weighted means (ranges) of point prevalence were 5.7% (0.9-13.5%) for women and 2.2% (0.2-7.3%) for men. According to continents, the weighted means (ranges) of point prevalence were 4.6% (2.0-13.5%) in America, 2.2% (0.2-13.1%) in Europe, and 3.5% (0.6-7.8%) in Asia.In addition to the former, 27 other studies reported the prevalence of EDs as broad categories resulting in weighted means (ranges) of total point prevalence of any EDs of 19.4% (6.5-36.0%) for women and 13.8% (3.6-27.1%) for men. CONCLUSIONS Despite the complexity of integrating all ED prevalence data, the most recent studies confirm that EDs are highly prevalent worldwide, especially in women. Moreover, the weighted means of point ED prevalence increased over the study period from 3.5% for the 2000-2006 period to 7.8% for the 2013-2018 period. This highlights a real challenge for public health and healthcare providers.
Collapse
Affiliation(s)
- Marie Galmiche
- TargEDys SA, Rouen, France.,Inserm UMR 1073, Institute for Research and Innovation in Biomedicine, Normandy Rouen University, France.,Department of Nutrition, Rouen University Hospital, Rouen, France
| | - Pierre Déchelotte
- Inserm UMR 1073, Institute for Research and Innovation in Biomedicine, Normandy Rouen University, France.,Department of Nutrition, Rouen University Hospital, Rouen, France
| | | | - Marie Pierre Tavolacci
- Inserm UMR 1073, Institute for Research and Innovation in Biomedicine, Normandy Rouen University, France.,ClC-CRB 1404, Rouen University Hospital, Rouen, France
| |
Collapse
|
8
|
Galmiche M, Deroissart C, Le Solliec MA, Rondeaux J, Azhar S, Achamrah N, Belmonte L, Lamarre A, Grigioni S, Folope V, Rimbert A, Saillard T, Delay J, Tavolacci M, Quillard M, Lambert G, Dechelotte P, Lucas N, Legrand R. Étude des neuropeptides plasmatiques et de leurs immunoglobulines respectives chez 120 patients atteints de troubles du comportement alimentaire. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Andreeva V, Tavolacci MP, Galan P, Ladner J, de Brauer Buscail C, Galmiche M, Hercberg S, Dechelotte P, Julia C. P301 Prévalences et déterminants sociodémographiques des troubles du comportement alimentaire (TCA) chez les adultes français. NUTR CLIN METAB 2018. [DOI: 10.1016/j.nupar.2018.09.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Andreeva VA, Tavolacci MP, Galan P, Ladner J, Buscail C, Péneau S, Galmiche M, Hercberg S, Déchelotte P, Julia C. Sociodemographic correlates of eating disorder subtypes among men and women in France, with a focus on age. J Epidemiol Community Health 2018; 73:56-64. [DOI: 10.1136/jech-2018-210745] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 07/19/2018] [Accepted: 09/10/2018] [Indexed: 11/04/2022]
Abstract
BackgroundOn the population level, the association of age and other sociodemographic factors with eating disorders (ED) is unclear.MethodsWe used cross-sectional data from the French general population-based NutriNet-Santé e-cohort (n=49 603 adults; 76.3% women; mean age=50.4±14.6 years). ED were evaluated in 2014 with the 5-item SCOFF screening questionnaire and the Expali algorithmic tool. Likely cases of restrictive, bulimic, hyperphagic and other ED were the dependent variables. Age, marital status, education, occupation, physical activity and smoking were the independent variables. Associations were estimated via gender-stratified multivariable polytomous logistic regression.ResultsAmong women, age displayed inverse linear associations with both restrictive and bulimic ED, underscoring 18–25 years as the most vulnerable period (adjusted OR=3.37, 95% CI: 2.24 to 5.08 for restrictive ED; adjusted OR=2.98, 95% CI: 2.37 to 3.74 for bulimic ED, respectively). A similar association was observed in men regarding bulimic ED. In women, age was not associated with hyperphagic ED for which living alone, low education, low physical activity, being a homemaker/disabled/unemployed/retired, a manual worker or a former/current smoker had increased importance. In men, 18–39 years emerged as the least vulnerable period regarding hyperphagic ED (adjusted OR=0.74, 95% CI: 0.56 to 0.99). Across gender, having postsecondary education had significant inverse associations with all except restrictive ED, whereas being a student had a significant positive association with restrictive ED.ConclusionsThe findings support gender-specific associations of age with four ED subtypes and could inform future prevention initiatives targeting specific ED among specific age groups.Trial registration numberNCT03335644; Pre-results.
Collapse
|
11
|
Belmonte L, Tavolacci M, Galmiche M, Achamrah N, Rimbert A, Delay J, Bole-Feysot C, Guérin C, Grigioni S, Folope V, Petit A, Coëffier M, Déchelotte P. MON-P057: Correlation between BMI and TLR4 and OB-R Expression on Monocytes in Patients with Eating Disorders. Clin Nutr 2017. [DOI: 10.1016/s0261-5614(17)31026-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Galmiche M, Monpetit S, Fintoni J, Schneider S, Hébuterne X. Bilan de 15ans de nutrition entérale à domicile en France : évolution des indications et des pratiques. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Grillot J, Galmiche M, Antunès O, Hébuterne X, Schneider SM. Conduite à tenir pratique pour l’exploration d’une malabsorption, d’une maldigestion, et d’une entéropathie exsudative. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.04.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
14
|
Galmiche M, Alessandrini E, Eyrault E, Kotovtchikhine A, Palomba K, Dorigny B, Schneider S, Darmon P, Hebuterne X. O08: Influence de la concentration des compléments nutritionnels oraux sur leur observance et les apports protéino-énergétiques des patients hospitalisés : résultats d’une étude randomisée en cluster. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70584-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Galmiche M, Besnard I, Palomba K, Eyraud E, Frin AC, Ouvrier D, Piche T, Schneider S, Hebuterne X. P262: Évaluation du caractère prédictif de l’échelle visuelle analogique (EVA) pour la détermination des ingesta des malades atteints d’un cancer. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70904-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Zaman K, Dahmane E, Perey L, Bodmer A, Anchisi S, Wolfer A, Galmiche M, Stravodimou A, Buclin T, Eap C, Decosterd L, Csajka C, Leyvraz S. Abstract P6-04-05: Tamoxifen dose escalation based on endoxifen level: a prospective trial with genotyping, phenotyping and pharmacokinetics over 4 months. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Retrospective studies assessing the impact of tamoxifen (Tam) metabolism and its active metabolite, endoxifen, on the efficacy of the treatment produced conflicting results. The prospective CYPTAM-BRUT 2 trial is ongoing1. In the present study we assessed if the level of Tam metabolites could be improved by doubling tamoxifen dose in breast cancer patients (pts) with any CYP2D6 genotype, poor (PM), intermediate (IM) and also extensive metabolizer (EM).
Patients and methods: This multicenter, prospective, open-label trial included pts treated with Tam for ≥ 4 months. CYP2D6 activity was determined centrally by genotyping and phenotyping (dextromethorphan test). Liquid chromatography-tandem-mass spectrometry was used to measure Tam, N-desmethyltamoxifen (N-DMT), 4-hydroxytamoxifen (4-HT) and endoxifen twice at baseline (Tam 20 mg qd), then at days 30, 90 and 120 after having increased the dose to 20 mg bid. Endoxifen increase and the differences between genotype/phenotype subgroups were analyzed by ANOVA.
Results: 76 pts were analyzed. Steady-state concentrations for Tam and its metabolites were reached in 30 days after doubling the dose. A range of 1.6 to 1.8 fold increase was observed. Geometric mean plasma concentrations in ng/ml (CV%) were: at baseline and day 30 respectively 134 (48) and 246 (46) for tamoxifen (p < 0.0001); 246 (53) and 413 (48) for N-DMT (p < 0.0001); 2.3 (44) and 3.7 (51) for 4HT (p < 0.0001); 18.7 (89) and 31.1 (92) for endoxifen (p = 0.005).
The level of endoxifen increased 1.4 to 1.7 folds in all genotype subgroups with geometric mean plasma concentrations in ng/ml (CV%): 6.9 (36) to 9.7 (24) in PMs (p = 0.7); 14.2 (69) to 20.7 (76) in IMs (p < 0.0001); and 22.6 (76) to 38.7 (85) in EMs (p < 0.0001). Similar results were obtained while considering phenotype subgroups. Genotypes and phenotypes explained less than 30% of the variability in endoxifen levels.
The occurrence of hot flashes and night sweating were followed prospectively. Endoxifen levels did not predict an increase in HF/NS events' overall occurrence (OR = 1.01, CI95% 0.78–1.31 for HF and 1.01, CI95% 0.79–1.29 for NS). Twelve pts received CYP2D6 inhibitors. Nine pts did not complete the planned 4 months with tamoxifen 20 mg bid. The main reasons were mood disorders, hot flashes, headache and nausea. Self-reported treatment compliance assessed by monthly anonymous questionnaire was ≥ 95%, except 80–95% in 4 pts.
Conclusions: This is the first trial reporting the impact of the increase of tamoxifen dose in all CYP2D6 genotypes, including EMs. Dose escalation of tamoxifen increased significantly the plasma level of endoxifen by similar ratio in all genotype subgroups.
Because of a huge inter-individual variability genotyping and phenotyping are not adequate surrogate markers of endoxifen level. Very low endoxifen levels are observed even in pts classified as EM.
Future trials aiming to improve the plasma level of endoxifen should consider direct measurement of the metabolite in plasma and adjust tamoxifen dose according to the initial level of the metabolite independently of the genotype.
Reference
1. A. Dieudonné, Journal of Clinical Oncology, 2011; vol 29, No 15, suppl (May 20, 2011): TPS 140
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-05.
Collapse
Affiliation(s)
- K Zaman
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - E Dahmane
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - L Perey
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - A Bodmer
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - S Anchisi
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - A Wolfer
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - M Galmiche
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - A Stravodimou
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - T Buclin
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - C Eap
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - L Decosterd
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - C Csajka
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| | - S Leyvraz
- University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland
| |
Collapse
|
17
|
Avella AC, Delgado LF, Görner T, Albasi C, Galmiche M, de Donato P. Effect of cytostatic drug presence on extracellular polymeric substances formation in municipal wastewater treated by membrane bioreactor. Bioresour Technol 2010; 101:518-526. [PMID: 19747822 DOI: 10.1016/j.biortech.2009.08.057] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2009] [Revised: 07/28/2009] [Accepted: 08/06/2009] [Indexed: 05/28/2023]
Abstract
The effect of the cyclophosphamide and its mean metabolites on extracellular polymeric substances (EPS) formation was investigated. Two lab-scale membrane bioreactors were followed in parallel (one with the cytostatic drugs, the second without). Chromatographic and spectroscopic studies (UV-Vis spectroscopy and IR spectroscopy) showed that the presence of CPs induced an increase in EPS concentration in the biological sludge, especially of soluble substances, mainly polysaccharides and proteins. Size exclusion chromatography analysis revealed that in the presence of CPs, macromolecular EPS were formed (polysaccharides corresponding to about 6 KDa and proteins to about 18 KDa). The formation of EPS seemed to be a protection mechanism. More important membrane fouling in reactor with CPs seemed to be related to the retention of an increased amount of soluble substances.
Collapse
Affiliation(s)
- A C Avella
- Laboratoire Environnement et Minéralurgie, Nancy-Université, CNRS, 15 avenue du Charmois, 54500 Vandoeuvre les Nancy, France.
| | | | | | | | | | | |
Collapse
|
18
|
Schmitt J, Trechot P, Jacquier A, Galmiche M, Netter P, Royer RJ. [Comparison of 63 months' drug monitoring between an internal medicine department and the entire university hospital]. Therapie 1983; 38:449-52. [PMID: 6670066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|